Johnson & Johnson reported results for the quarter ended 2026 with revenue of $25.31B and diluted EPS of $2.27, compared with $23.74B and $2.29 in the year-ago quarter; net earnings were $5.53B versus $5.54B a year earlier.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$25.31B$23.74B6.6% | Net income²$5.53B$5.54B(0.1%) | Diluted EPS³$2.27$2.29(0.9%) |
¹ Reported as “Sales to customers (Note 9)”. ² Reported as “Net earnings”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue growth was driven by momentum in Oncology (DARZALEX, CARVYKTI, TECVAYLI) and Neuroscience (SPRAVATO, CAPLYTA), supporting share gains and new launches.
- Innovative Medicine grew about 7.1% operationally while MedTech rose roughly 4.1% YTD (6 months); international sales increased ~8.7% with a currency tailwind, and Europe and the Western Hemisphere posted double-digit growth aided by FX.
- Immunology faced material declines due to STELARA biosimilars; SIMPONI biosimilars are emerging in Europe, creating competitive headwinds.
- Company began supply-chain restructuring targeting $650–$750M in benefits and continued planning for the MedTech orthopaedics separation.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.